Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified?
Publication
, Journal Article
Ovadia, A; Abern, M
Published in: Eur Urol
July 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
July 2015
Volume
68
Issue
1
Start / End Page
40 / 41
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Registries
- Prostatic Neoplasms
- Orchiectomy
- Male
- Humans
- Antineoplastic Agents, Hormonal
- Androgen Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ovadia, A., & Abern, M. (2015). Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified? Eur Urol, 68(1), 40–41. https://doi.org/10.1016/j.eururo.2014.10.046
Ovadia, Aaron, and Michael Abern. “Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified?” Eur Urol 68, no. 1 (July 2015): 40–41. https://doi.org/10.1016/j.eururo.2014.10.046.
Ovadia A, Abern M. Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified? Eur Urol. 2015 Jul;68(1):40–1.
Ovadia, Aaron, and Michael Abern. “Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified?” Eur Urol, vol. 68, no. 1, July 2015, pp. 40–41. Pubmed, doi:10.1016/j.eururo.2014.10.046.
Ovadia A, Abern M. Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified? Eur Urol. 2015 Jul;68(1):40–41.
Published In
Eur Urol
DOI
EISSN
1873-7560
Publication Date
July 2015
Volume
68
Issue
1
Start / End Page
40 / 41
Location
Switzerland
Related Subject Headings
- Urology & Nephrology
- Registries
- Prostatic Neoplasms
- Orchiectomy
- Male
- Humans
- Antineoplastic Agents, Hormonal
- Androgen Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences